Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Guggenheim

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

MongoDB Scores Best Day Ever After Earnings Beat—Here's What Wall Street Thinks

MongoDB Inc. (NASDAQ:MDB) is enjoying its biggest one-day rally since going public in 2017.

This Gap Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

inkl

Read news from The Economist, FT, and more,
with one subscription

Jim Cramer Says Newly Merged Paramount Skydance Is a Meme Stock. Should You Buy PSKY Here?

Jim Cramer Says Newly Merged Paramount Skydance Is a Meme Stock. Should You Buy PSKY Here?

The newly formed Paramount Skydance's stock just earned its meme stock fame and surged. Should investors dive in or approach cautiously?

Tesla Is Ramping Up Its Robotaxi Plans. What Does That Mean for TSLA Stock?

Tesla Is Ramping Up Its Robotaxi Plans. What Does That Mean for TSLA Stock?

Tesla is reportedly looking for robotaxi employees in the New York City. Guggenheim still sees potential for a 50% crash in TSLA shares.

Paramount Skydance Soars on UFC White House Fight Plans and Guggenheim Buy Rating

Paramount Skydance Soars on UFC White House Fight Plans and Guggenheim Buy Rating

Paramount Skydance Corporation (NASDAQ:PSKY) shares are trading higher Wednesday after Guggenheim initiated coverage on the stock with a Buy rating and a $13 price target.

Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Datadog Raises Full-Year Outlook After 125+ AI Feature Launches, But OpenAI Pullback Clouds Long-Term Growth

Datadog Raises Full-Year Outlook After 125+ AI Feature Launches, But OpenAI Pullback Clouds Long-Term Growth

Datadog (NASDAQ:DDOG) reported its quarterly results on Thursday.

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Meta To Rally More Than 56%? Here Are 10 Top Analyst Forecasts For Thursday

Meta To Rally More Than 56%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Get all your
news in one place.

100's of premium titles.
One news app.

Alphabet To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

CoreWeave, Mobileye And First Solar Are Among Top 10 Large Cap Losers Last Week (July 7-July 11): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Datadog Stock Falls After Guggenheim Downgrade, Citing OpenAI Spending Risks

Datadog Inc (NASDAQ:DDOG) shares are trading lower Tuesday after analysts at Guggenheim downgraded the stock from Neutral to Sell, setting a new price target of $105.

Get all your
news in one place.

100's of premium titles.
One news app.

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500

Last week saw Tesla receiving both firm Sell rating and firm Buy ratings. This is a rare event, but upon closer expectation, the stock knows what it wants.

Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Can Oracle Stock Hit $250 in 2025?

With Guggenheim raising Oracle’s target to $250, can the Big Red actually hit that mark before year-end?

Oracle Stock Boils Higher, $300 Price Target in Sight

Oracle is well-positioned to accelerate its growth, and its stock price reflects this; analyst and technical signals suggest a move above $300 is coming soon.

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

1 2 3 4 5

People

Patrick Walravens

Blair Abernethy

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

404,394 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play